Humedix (KRX 200670) Stock Outlook 2026: A Prescription Cash Cow Wearing an Aesthetics Growth Costume
Humedix (KRX: 200670) 2026 stock outlook, analyzed qualitatively. A hyaluronic-acid platform spans a defensive prescription cash cow — the Hyruan osteoarthritis knee injection — and a cyclical aesthetics growth engine in Elravie dermal fillers, plus toxin expansion, CDMO, and Huons Group distribution. We weigh the moat, the China NMPA export lever, and the competitive risks from LG Chem, Hugel and Jetema.
Humedix 200670 Korea Stocks
